Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About
Leadership
Pipeline
Publications
Newsroom
Contact
Newsroom
Press Releases
Media Contact
News Alerts
Press Releases
Sparian Biosciences Joins U.S. Senate Panel in Fighting Fentanyl
June 5, 2024
Sparian Biosciences Urges U.S. Senate to Support NIH’s Fight Against Substance Abuse
May 23, 2024
Sparian Biosciences Awarded $19 Million Five-Year NIH/NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
August 8, 2023
Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain
February 23, 2023
Sparian Biosciences Announces IND Clearance of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain by the U.S. FDA
February 9, 2023
Media Contact
Annie Pasternak
Chief Operating Officer
Sparian Biosciences
contact@sparianbiosciences.com
Subscribe to Receive News Alerts
Fill out my
online form
.
Close Menu
About
Leadership
Pipeline
Publications
Newsroom
Contact
twitter
linkedin
email